New research suggests that the weight-loss medication semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, could be manufactured for as little as $3 (£2.35) per month. This development holds the potential to broaden access to essential healthcare solutions for millions grappling with obesity and diabetes across 160 nations, particularly in lower-income regions.
A Game-Changer for Global Health
Semaglutide was designated as an essential medicine by the World Health Organization (WHO) in September 2022, reflecting its significant role in treating chronic conditions. However, the prohibitive cost of existing treatments has hindered access, particularly in developing nations where obesity rates are surging, largely due to the adoption of Western diets and sedentary lifestyles.
A recent pre-print study reveals that mass production of semaglutide could lead to monthly treatment costs as low as $3 for the injectable form. For newer pill formulations, the estimated cost could hover around $16 monthly. Dr Andrew Hill from Liverpool University, one of the study’s authors, emphasised that these reduced prices could facilitate global access to this critical medication.
Patents and Production: A Path to Accessibility
The research highlights that core patents for semaglutide are set to expire in ten countries, including Brazil, China, India, South Africa, Turkey, Mexico, and Canada, starting from 21 March 2026. This could pave the way for generic manufacturers to enter the market, fostering competition that drives prices even lower. Furthermore, the authors identified an additional 150 countries—primarily in Africa—where no patent protections have been filed, encompassing approximately 69% of individuals with type 2 diabetes and 84% of those living with obesity globally.
Prof François Venter from Witwatersrand University in Johannesburg noted that the success of affordable treatments for conditions like HIV, tuberculosis, and malaria could be replicated for semaglutide. He stated, “We can repeat this medical success story for semaglutide,” suggesting that with the right market conditions, sustainable supply chains can be established.
Addressing Structural Barriers
While the prospect of cheaper semaglutide is promising, researchers caution that simply reducing medication costs will not resolve the underlying structural factors contributing to obesity, such as food insecurity, poverty, and unhealthy urban environments. Dr Nomathemba Chandiwana, chief scientific officer at the Desmond Tutu Health Foundation in South Africa, stressed that effective integration of these medications into existing healthcare frameworks is essential for maximising their impact.
Chandiwana further revealed that approximately 27% of adults worldwide could benefit from drugs like semaglutide, with a significant proportion residing in low- and middle-income countries (LMICs) where access remains a challenge. The key question now revolves around how health systems will responsibly incorporate these medications into broader obesity and diabetes management strategies.
The Rising Tide of Diabetes
The urgency of addressing obesity and diabetes cannot be overstated. The number of individuals living with diabetes has skyrocketed from 200 million in 1990 to a staggering 830 million in 2022, with the highest growth rates in LMICs. Obesity is linked to various health complications, including heart disease, stroke, and certain cancers, contributing to approximately 3.7 million deaths annually due to excess weight.
Semaglutide, first approved in the United States in 2017, is currently priced at about $200 per month in the US and £120 in the UK, with patent protections in these regions remaining for another five years. The implications of this new research, which utilises shipment records of key ingredients and established methodologies used for predicting generic medicine pricing, could alter the landscape of diabetes and obesity treatment significantly.
Why it Matters
The potential for affordable semaglutide production signifies a transformative shift in global health, especially for those in developing nations where diabetes and obesity rates are escalating. By lowering the financial barriers to accessing essential medications, we could see a marked improvement in public health outcomes. However, this opportunity must be paired with comprehensive strategies that tackle the root causes of these conditions to create sustainable, long-term health solutions.